Miltenyi Biomedicine at BIO-Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
Miltenyi Biomedicine takes part in 3 sessions at BIO-Europe 2026 in Cologne. Its sessions centre on advanced and cellular therapies, and on getting them from clinical success to patients across Europe. The most distinctive covers where oncology and autoimmune disease meet in cellular therapies.
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Miltenyi Biomedicine Bergisch Gladbach, Germany | |
Clinical-stage company of the Miltenyi Group developing CAR-T and other cell therapies for cancer and autoimmune disease. | Panel Tue Nov 10 10:00–10:45 Accelerating Access to Innovative Therapies for European Patients Through Integrated Decision-Making How approval, benefit reviews and pricing decisions could run side by side instead of one after another, so European patients get new medicines sooner. Panel Tue Nov 10 09:30–09:55 From Clinical Success to Commercial Readiness: Strategic Lessons in Bringing Advanced Therapies to Patients Lessons from preparing cell and gene therapies for launch by planning manufacturing, approval and reimbursement alongside the clinical trials. Talk Wed Nov 11 09:30–09:55 Bridging Therapeutic Areas: Navigating the Oncology–Autoimmune Convergence in Cellular Therapies What changes when cell therapies first developed for cancer move into autoimmune disease, from acceptable safety risks and trial endpoints to manufacturing. |
Instantly find 20 buyers from Miltenyi Biomedicine
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction